Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME).
Fiche publication
Date publication
juillet 2021
Journal
ESMO open
Auteurs
Membres identifiés du Cancéropôle Est :
Dr COUDERT Bruno, Pr PETIT Thierry
Tous les auteurs :
Dano D, Lardy-Cleaud A, Monneur A, Quenel-Tueux N, Levy C, Mouret-Reynier MA, Coudert B, Mailliez A, Ferrero JM, Guiu S, Campone M, de La Motte Rouge T, Petit T, Pistilli B, Dalenc F, Simon G, Lerebours F, Chabaud S, Bertucci F, Gonçalves A
Lien Pubmed
Résumé
Primary inflammatory breast cancer (IBC) is a rare and aggressive entity whose prognosis has been improved by multimodal therapy. However, 5-year overall survival (OS) remains poor. Given its low incidence, the prognosis of IBC at metastatic stage is poorly described.
Mots clés
inflammatory breast cancer, metastatic breast cancer, multimodal therapy, prognostic factors, real-life study
Référence
ESMO Open. 2021 Jul 22;6(4):100220